T1	SectionAnnotate 147 174	HISTORY OF PRESENT ILLNESS:
T2	SectionSkip 1626 3179	Pathology revealed 4.6cm pancreatic head adenocarcinoma with +PNI, +SM at the SMA margin with 11/46 lymph nodes positive. His postoperative course was complicated by a wound infection in his left neck incision and he was discharged to a SNF where he required 1 month of rehab and was discharged home on 03/24/18.  04/15/18: 
 CT CAP reports ill defined stranding in surgical resection bed consistent with recurrence or post-surgical changes with significant portal vein anastamosis narrowing. No evidence of metastatic disease.  04/21/18: Consultation with Dr. *****. He presented TB's recommendations: Given patient's high risk of recurrence with + margins at the SMA and many LNs involved, it was recommended that patient receive XRT and then systemic therapy   05/04/18: Consultation with Dr. *****. Recommendations: Repeat PET/CT prior to start of radiotherapy. IMRT auth submitted, anticipate 28 fractions - plan for CT sim in ~2 weeks after resolution of C dificile infection. Return to clinic in 2 weeks for further discussion with same day sim.    May 2018: Patient developed ascites and has required weekly paracentesis. Ascites fluid is negative for malignancy and not KRAS mutated. Ascites likley related to CT finding of portal vein stenosis, which is likely from surgery; no evidence of thrombus.   June 2018: Portal vein stented. Improvement in Ascites.   September 08: Neg PET CT  October 08: neg abd U/s, no ascites.     accompanied by Daughter ***** ***** today.  He's doing pretty weel..   HgBA1C running >12  No pain. Wounds improved.
T3	SectionAnnotate 3187 3204	Review of Systems
T4	SectionAnnotate 4064 4085	Past Medical History:
T5	SectionAnnotate 4415 4437	Past Surgical History:
T6	SectionSkip 4920 7486	Current Medications       Dosage    acetaminophen (TYLENOL) 500 mg tablet Take 1,000 mg by mouth 2 (two) times daily as needed for Pain.     alpha-D-galactosidase (BEANO ORAL) Take by mouth. not taking, patient do not have supplies    blood glucose (BLOOD GLUCOSE) test strip Check blood sugar 4x daily, as directed    blood-glucose monitoring kit Check glucose daily as directed by provider    calcium carbonate (TUMS ORAL) Take 1,000 mg by mouth once as needed.    calcium citrate/vitamin D3 (CALCIUM CITRATE + D ORAL) Take by mouth Daily.    cholecalciferol, vitamin D3, 1000 UNITS TAB tablet Take 1,000 Units by mouth Daily.    clotrimazole 1 mg/mL SUSP suspension Take by mouth daily as needed. buccal    empty container (SHARPS CONTAINER) MISC Sharps Container: Use as directed to discard insulin needles and lancets with each use.    enoxaparin (LOVENOX) 80 mg/0.8 mL injection Inject 60 mg under the skin every 12 (twelve) hours.     famotidine 
 (PEPCID) 10 mg tablet Take 10 mg by mouth 2 (two) times daily as needed (indigestion).    folic acid/multivit-min/lutein (CENTRUM SILVER ORAL) Take by mouth Daily.    furosemide (LASIX) 20 mg tablet Take 20 mg by mouth Daily.     glucose 4 gram chewable tablet When Blood sugar <70mg/dL, chew and swallow 20grams (5 tablets) and restest blood sugar in 15 minutes to goal blood sugar >100mg/dL    insulin aspart U-100 (NOVOLOG) 100 unit/mL injection Inject under the skin three times daily with meals and at bedtime according to your insulin sliding scale    insulin glargine (LANTUS) 100 unit/mL injection Inject 14 Units under the skin Daily. Or as directed. Note that your dose may change.    insulin syringe-needle U-100 (BD INSULIN SYRINGE ULTRA-FINE) 0.3 mL 31 gauge x August 05" SYRINGE syringe Use four times daily as directed.    lancets lancets Check blood sugar 4x per day as directed.    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit CAPDREC capsule Take 6 capsules by mouth 3 (three) times daily. 3 capsules with snacks    multivitamin complete chewable (FLINTSTONES COMPLETE) chewable tablet Take 1 tablet by mouth Daily.    pantoprazole (PROTONIX) 40 mg EC tablet Take 40 mg by mouth 2 (two) times daily.    rifAXIMin (XIFAXAN) 550 mg tablet Take 550 mg by mouth 2 (two) times daily.    rivaroxaban (XARELTO) 20 mg tablet Take 20 mg by mouth Daily. On hold by *****. ***** ***** / pt is on Lovenox - SFGH    Saccharomyces boulardii (FLORASTOR) 250 mg capsule Take 250 mg by mouth 2 (two) times daily.    vancomycin (VANCOCIN) 125 mg capsule Take 125 mg by mouth 4 (four) times daily.
T7	SectionAnnotate 8579 8593	Social History
T8	SectionSkip 9803 11058	OBJECTIVE ASSESSMENT  BP 146/70  | Pulse 88  | Temp 37.3 C (99.2 F) (Temporal)  | Resp 16  | Ht 175.5 cm (5' 9.09")  | Wt 70.9 kg (156 lb 3.2 oz)  | SpO2 99%  | BMI 23.00 kg/m     ECOG: 1   Physical Exam   Nursing note and vitals reviewed.  Constitutional: He is oriented to person, place, and time. He appears well-developed and well-nourished.   HENT:   Head: Normocephalic and atraumatic.   Nose: Nose normal.   Eyes: Conjunctivae and EOM are normal. Left eye exhibits no discharge. No scleral icterus.   Neck: Neck supple. No JVD present. No tracheal deviation present. No thyromegaly present.   Cardiovascular: Normal rate, regular rhythm and normal heart sounds.   No murmur heard.  Pulmonary/Chest: Breath sounds normal. No respiratory distress. He has no wheezes.   Abdominal: Bowel sounds are normal. He exhibits distension. He exhibits no mass. There is no tenderness. There is no rebound.   Musculoskeletal: Normal range of motion. He exhibits no edema, tenderness or deformity.   Neurological: He is alert and oriented to person, place, and time. He has normal reflexes. Coordination normal.   Skin: Skin is warm and dry. No rash noted. No pallor.   Psychiatric: He has a normal mood and affect. His behavior is normal. Thought content normal.
T9	SectionSkip 9993 11058	Physical Exam   Nursing note and vitals reviewed.  Constitutional: He is oriented to person, place, and time. He appears well-developed and well-nourished.   HENT:   Head: Normocephalic and atraumatic.   Nose: Nose normal.   Eyes: Conjunctivae and EOM are normal. Left eye exhibits no discharge. No scleral icterus.   Neck: Neck supple. No JVD present. No tracheal deviation present. No thyromegaly present.   Cardiovascular: Normal rate, regular rhythm and normal heart sounds.   No murmur heard.  Pulmonary/Chest: Breath sounds normal. No respiratory distress. He has no wheezes.   Abdominal: Bowel sounds are normal. He exhibits distension. He exhibits no mass. There is no tenderness. There is no rebound.   Musculoskeletal: Normal range of motion. He exhibits no edema, tenderness or deformity.   Neurological: He is alert and oriented to person, place, and time. He has normal reflexes. Coordination normal.   Skin: Skin is warm and dry. No rash noted. No pallor.   Psychiatric: He has a normal mood and affect. His behavior is normal. Thought content normal.
T13	SectionSkip 11596 11878	Lab Results   Component Value Date    Bilirubin, Total 0.5 09/05/2018    Alkaline Phosphatase 665 (H) 09/05/2018    Aspartate 
 transaminase 101 (H) 09/05/2018    Alanine transaminase 58 09/05/2018    Albumin, Serum / Plasma 3.3 (L) 09/05/2018    Int'l Normaliz Ratio 1.0 05/24/2018
T16	SectionSkip 12430 15959	FINAL PATHOLOGIC DIAGNOSIS  A. Soft tissue, "superior mesenteric artery margin," biopsy:   Adenocarcinoma; see comment.   B. Celiac lymph node, biopsy: Metastatic adenocarcinoma in one lymph  node (March 22).  C. Gallbladder, cholecystectomy: Mild chronic cholecystitis.  D. Spleen, splenectomy:   1. Spleen (564 grams) with no significant pathologic abnormality.  2. No tumor in two lymph nodes (0/2).    E. Pancreas, tail and body, distal pancreatectomy:  1. Ductal adenocarcinoma; see comment.   2. Chronic pancreatitis, extensive.   3. No tumor in twenty-six lymph nodes (0/26).       F. Pancreas, duodenum, portal vein, pancreaticoduodenectomy:  1. Ductal adenocarcinoma, moderately-differentiated, 4.6 cm, involving  duodenal wall; see comment  2. Chronic pancreatitis, extensive.   3. Pancreatic intraepithelial neoplasia, high-grade.   4. Adenocarcinoma in ten lymph nodes (January 06).    COMMENT:  PANCREAS SYNOPTIC COMMENT  - Tumor Location: Pancreatic head.  - Procedure: Pancreaticoduodenectomy.  - Size: Unifocal, 4.6 cm.  - Histologic Type: Ductal adenocarcinoma (slides F1, F4, F5, and  F8-F15).  - Histologic Grade of Invasive Carcinoma: Moderately-differentiated  (status post treatment).  - Microscopic 
 Tumor Extension: Tumor invades duodenum and tunica media  of portal vein.     - Lymphovascular Invasion: Not identified.  - Perineural Invasion: Present.  - Margins:    Superior mesenteric artery margin: In the separately submitted "SMA  margin" (part A) invasive adenocarcinoma is present on permanent and  deeper level sections performed on block A1. Adenocarcinoma was not  present on the slides evaluated for frozen section diagnosis.     Uncinate (Retroperitoneal) Margin: For the pancreaticoduodenectomy  specimen (part F), invasive carcinoma is less than 0.1 cm from  cauterized margin on slide F5.   Bile Duct Margin: Negative for invasive carcinoma and high-grade  dysplasia, invasive carcinoma is 0.5 cm from margin.  Portal Vein Margin: Both the superior and inferior portal vein margins  are negative for invasive carcinoma. Invasive carcinoma is 0.8 cm from  the superior portal vein margin and 2.3 cm from the inferior portal vein  margin.   Pancreatic Neck Margin: For the pancreaticoduodenectomy specimen (part  F), the pancreatic neck margin is positive for invasive adenocarcinoma  on slide F1. For the distal pancreatectomy specimen (part E), a focus of  invasive carcinoma is present at the proximal pancreatic margin.  Correlation with operative findings is recommended to determine if  either of these represents a true surgical margin.   Proximal Intestinal Margin: Negative for invasive carcinoma, invasive  carcinoma is 6 cm from the margin.  Distal Intestinal Margin (Distal Duodenal or Jejunal): Negative for  invasive carcinoma, invasive carcinoma is 9 cm from the margin.  - Posterior pancreatic surface: Negative, invasive carcinoma is 0.1 cm  from this surface on slide F13.   - Anterior pancreatic surface: Negative, invasive carcinoma is 1 cm  from this surface on slide F12.  - Treatment Effect: Residual tumor on slides E1, F1, F4, F5, and  F8-F16.    Evans grading system (grade I-IV): 
 Grade I, little (<10%) or no  tumor cell destruction.     Modified Ryan scheme for tumor regression (score 0-3): Score 3,  poor or no response (extensive residual cancer with no evident tumor  regression).  - Regional Lymph Nodes: Positive.    Total number of positive nodes: 11.    Nodes involved by direct extension: 4.     Total number of nodes examined: 46.  - Other Pathologic
T18	SectionAnnotate 16493 16504	Impression:
T19	PROBLEM 117 143	resected pancreatic cancer
T20	TEST 214 224	evaluation
T21	PROBLEM 228 258	his resected pancreatic cancer
T22	ClinicalCondition 390 400	type II DM
T23	Symptom 452 469	painless jaundice
T24	Symptom 474 488	acholic stools
T25	ClinicalCondition 511 524	transaminitis
T26	PROBLEM 526 544	hyperbilirubinemia
T27	PROBLEM 550 579	a mass at the pancreatic head
T28	TEST 609 625	an endoscopic US
T29	TREATMENT 627 642	stent placement
T30	PROBLEM 646 670	the stricture at the CBD
T31	TEST 676 694	a biopsy/brushings
T32	PROBLEM 706 712	A mass
T33	TEST 752 774	Fine needle aspiration
T34	PROBLEM 790 804	atypical cells
T35	PROBLEM 852 872	Hyperechoic material
T36	PROBLEM 889 895	sludge
T37	PROBLEM 964 1024	significant pathology in the visualized portion of the liver
T38	TREATMENT 1038 1047	the stent
T39	PROBLEM 1079 1110	upward trending total bilirubin
T40	TEST 1112 1118	Biopsy
T41	RadPathResult 1142 1156	adenocarcinoma
T42	Radiology 1162 1187	a CT abd/pelvis and chest
T43	PROBLEM 1194 1219	stage 3 local advancement
T44	PROBLEM 1240 1258	distant metastasis
T45	ProcedureName 1284 1297	Surgical Eval
T46	TEST 1318 1331	surgical eval
T47	TREATMENT 1352 1374	neoadjuvant FOLFIRINOX
T48	TEST 1387 1394	CT scan
T49	PROBLEM 1407 1422	e/o progression
T50	TREATMENT 1514 1538	pancreatico-duodenectomy
T51	TREATMENT 1544 1567	pancreatico-jejunostomy
T52	PROBLEM 1588 1592	mass
T53	TEST 1626 1635	Pathology
T54	PROBLEM 1645 1681	4.6cm pancreatic head adenocarcinoma
T55	PROBLEM 1688 1691	PNI
T56	PROBLEM 1694 1714	SM at the SMA margin
T57	PROBLEM 1726 1746	lymph nodes positive
T58	PROBLEM 1792 1835	a wound infection in his left neck incision
T59	TEST 1952 1954	CT
T60	PROBLEM 1967 2014	ill defined stranding in surgical resection bed
T61	PROBLEM 2031 2041	recurrence
T62	PROBLEM 2045 2066	post-surgical changes
T63	PROBLEM 2072 2117	significant portal vein anastamosis narrowing
T64	PROBLEM 2134 2152	metastatic disease
T65	PROBLEM 2258 2268	recurrence
T66	PROBLEM 2274 2294	+ margins at the SMA
T67	TREATMENT 2358 2361	XRT
T68	TREATMENT 2371 2387	systemic therapy
T69	TEST 2446 2459	Repeat PET/CT
T70	TREATMENT 2478 2490	radiotherapy
T71	TEST 2548 2554	CT sim
T72	PROBLEM 2587 2607	C dificile infection
T73	ClinicalCondition 2710 2717	ascites
T74	TREATMENT 2735 2754	weekly paracentesis
T75	PROBLEM 2756 2769	Ascites fluid
T76	PROBLEM 2786 2796	malignancy
T77	PROBLEM 2805 2809	KRAS
T78	PROBLEM 2819 2826	Ascites
T79	TEST 2845 2855	CT finding
T80	PROBLEM 2859 2879	portal vein stenosis
T81	TREATMENT 2902 2909	surgery
T82	PROBLEM 2926 2934	thrombus
T83	TREATMENT 2949 2968	Portal vein stented
T84	PROBLEM 2985 2992	Ascites
T85	TEST 3014 3020	PET CT
T86	TEST 3038 3045	abd U/s
T87	PROBLEM 3050 3057	ascites
T88	TEST 3134 3140	HgBA1C
T89	PROBLEM 3157 3161	pain
T90	PROBLEM 3163 3169	Wounds
T91	PROBLEM 3236 3242	chills
T92	PROBLEM 3244 3249	fever
T93	PROBLEM 3254 3261	malaise
T94	PROBLEM 3262 3269	fatigue
T95	PROBLEM 3322 3335	double vision
T96	PROBLEM 3340 3344	pain
T97	PROBLEM 3374 3379	cough
T98	Symptom 3384 3403	shortness of breath
T99	Symptom 3437 3449	palpitations
T100	Symptom 3451 3463	claudication
T101	Symptom 3465 3477	leg swelling
T102	Symptom 3482 3485	PND
T103	Symptom 3531 3545	abdominal pain
T104	Symptom 3547 3561	blood in stool
T105	Symptom 3563 3571	diarrhea
T106	Symptom 3576 3584	vomiting
T107	Symptom 3627 3634	dysuria
T108	Symptom 3636 3645	hematuria
T109	Symptom 3650 3657	urgency
T110	Symptom 3702 3712	joint pain
T111	Symptom 3717 3726	neck pain
T112	Symptom 3760 3764	rash
T113	Symptom 3795 3803	tingling
T114	Symptom 3805 3818	speech change
T115	Symptom 3820 3834	focal weakness
T116	Symptom 3839 3848	headaches
T117	Symptom 3900 3910	depression
T118	Symptom 3914 3928	hallucinations
T119	PROBLEM 3977 3984	anxious
T120	PROBLEM 4003 4011	insomnia
T121	TEST 4016 4033	All other systems
T122	ClinicalCondition 4107 4116	Arthritis
T123	TREATMENT 4133 4168	continuous positive airway pressure
T124	TREATMENT 4170 4183	CPAP) therapy
T125	TreatmentType 4246 4250	CPAP
T126	ClinicalCondition 4255 4269	Hyperlipidemia
T127	ClinicalCondition 4275 4309	Pancreatic mass     adenocarcinoma
T128	PROBLEM 4349 4363	active disease
T129	Radiology 4369 4372	CXR
T130	ClinicalCondition 4377 4402	Type II diabetes mellitus
T131	TREATMENT 4470 4482	APPENDECTOMY
T132	TEST 4501 4505	ERCP
T133	TREATMENT 4520 4535	stent placement
T134	PROBLEM 4540 4553	CBD stricture
T135	TREATMENT 4564 4578	replaced stent
T136	TREATMENT 4592 4609	IR PORT PLACEMENT
T137	TREATMENT 4775 4800	LAPAROSCOPIC APPENDECTOMY
T138	TREATMENT 4825 4840	STENT PLACEMENT
T139	PROBLEM 4846 4867	Bile duct in pancreas
T140	TREATMENT 4884 4906	TONSILLECTOMY      ca.
T141	TREATMENT 4920 4979	Current Medications       Dosage    acetaminophen (TYLENOL)
T142	PROBLEM 5051 5055	Pain
T143	TREATMENT 5061 5095	alpha-D-galactosidase (BEANO ORAL)
T144	TEST 5155 5168	blood glucose
T145	TEST 5170 5183	BLOOD GLUCOSE
T146	TEST 5185 5195	test strip
T147	TEST 5202 5213	blood sugar
T148	TEST 5239 5263	blood-glucose monitoring
T149	TREATMENT 5315 5344	calcium carbonate (TUMS ORAL)
T150	TREATMENT 5387 5402	calcium citrate
T151	TREATMENT 5403 5440	vitamin D3 (CALCIUM CITRATE + D ORAL)
T152	TREATMENT 5465 5480	cholecalciferol
T153	TREATMENT 5482 5492	vitamin D3
T154	TREATMENT 5552 5564	clotrimazole
T155	TREATMENT 5620 5664	buccal    empty container (SHARPS CONTAINER)
T156	TREATMENT 5715 5730	insulin needles
T157	TREATMENT 5761 5781	enoxaparin (LOVENOX)
T158	TREATMENT 5862 5883	famotidine 
 (PEPCID)
T159	TREATMENT 5965 5975	folic acid
T160	TREATMENT 5976 5995	multivit-min/lutein
T161	TREATMENT 6042 6060	furosemide (LASIX)
T162	TEST 6105 6112	glucose
T163	TEST 6141 6152	Blood sugar
T164	TREATMENT 6172 6179	swallow
T165	TEST 6212 6223	blood sugar
T166	TEST 6246 6257	blood sugar
T167	TREATMENT 6271 6287	insulin aspart U
T168	TREATMENT 6293 6301	NOVOLOG)
T169	TREATMENT 6403 6458	your insulin sliding scale    insulin glargine (LANTUS)
T170	TREATMENT 6570 6585	insulin syringe
T171	TREATMENT 6600 6630	BD INSULIN SYRINGE ULTRA-FINE)
T172	TEST 6735 6746	blood sugar
T173	TREATMENT 6774 6805	lipase-protease-amylase (CREON)
T174	TREATMENT 6924 6977	multivitamin complete chewable (FLINTSTONES COMPLETE)
T175	TREATMENT 7027 7050	pantoprazole (PROTONIX)
T176	TREATMENT 7111 7130	rifAXIMin (XIFAXAN)
T177	TREATMENT 7190 7211	rivaroxaban (XARELTO)
T178	TREATMENT 7293 7300	Lovenox
T179	TREATMENT 7303 7346	SFGH    Saccharomyces boulardii (FLORASTOR)
T180	TREATMENT 7407 7428	vancomycin (VANCOCIN)
T181	PROBLEM 7496 7505	Allergies
T182	TREATMENT 7526 7544	Allergen Reactions
T183	TREATMENT 7549 7560	Ondansetron
T184	PROBLEM 7561 7569	Wheezing
T185	PROBLEM 7579 7587	wheezing
T186	Site 7589 7595	throat
T187	PROBLEM 7625 7650	Some coarseness in throat
T188	TREATMENT 7681 7692	Oxaliplatin
T189	PROBLEM 7746 7754	numbness
T191	MedicationName 7809 7820	Benadryl IV
T192	MedicationName 7827 7841	hydrocortisone
T193	TREATMENT 7849 7875	remaining chemo irinotecan
T194	TREATMENT 7880 7890	leucovorin
T195	PROBLEM 7909 7921	complication
T196	Symptom 7939 7958	heaviness of tongue
T197	Symptom 7963 7989	numbness at back of throat
T198	TREATMENT 7995 8012	Sodium Phosphates
T199	Symptom 8038 8046	Wheezing
T200	TREATMENT 8085 8103	saline fleet enema
T201	Symptom 8115 8123	wheezing
T202	Symptom 8128 8143	chest tightness
T203	PROBLEM 8302 8321	redness on his lips
T204	TREATMENT 8326 8337	Penicillins
T205	PROBLEM 8363 8386	Numbness on right thigh
T206	PROBLEM 8387 8401	minor reaction
T207	PROBLEM 8431 8450	heaviness of tongue
T208	PROBLEM 8452 8478	numbness at back of throat
T209	MedicationName 8491 8500	ertapenem
T210	MedicationName 8505 8516	fleet enema
T211	TEST 9825 9827	BP
T212	TEST 9838 9843	Pulse
T213	TEST 9850 9854	Temp
T214	TEST 9860 9861	C
T215	TEST 9885 9889	Resp
T216	TEST 9896 9898	Ht
T217	TEST 9922 9924	Wt
T218	TEST 9952 9956	SpO2
T219	TEST 9964 9967	BMI
T220	TEST 10026 10032	vitals
T221	PROBLEM 10183 10193	atraumatic
T222	PROBLEM 10292 10307	scleral icterus
T223	PROBLEM 10333 10336	JVD
T224	PROBLEM 10349 10367	tracheal deviation
T225	PROBLEM 10380 10391	thyromegaly
T226	PROBLEM 10477 10483	murmur
T227	TEST 10509 10522	Breath sounds
T228	PROBLEM 10534 10554	respiratory distress
T229	PROBLEM 10566 10573	wheezes
T230	PROBLEM 10625 10635	distension
T231	PROBLEM 10652 10656	mass
T232	PROBLEM 10670 10680	tenderness
T233	PROBLEM 10694 10701	rebound
T234	PROBLEM 10761 10766	edema
T235	PROBLEM 10768 10778	tenderness
T236	PROBLEM 10782 10791	deformity
T237	PROBLEM 10940 10944	rash
T238	PROBLEM 10955 10961	pallor
T239	TEST 11210 11213	WBC
T240	TEST 11214 11219	Count
T241	TEST 11238 11248	Neutrophil
T242	TEST 11249 11263	Absolute Count
T243	TEST 11283 11293	Hemoglobin
T244	TEST 11299 11300	L
T245	TEST 11316 11326	Hematocrit
T246	TEST 11350 11364	Platelet Count
T247	TEST 11384 11395	Lab Results
T248	TEST 11408 11413	Value
T249	TEST 11422 11432	Creatinine
T250	TEST 11452 11458	Sodium
T251	TEST 11460 11465	Serum
T252	TEST 11468 11474	Plasma
T253	TEST 11480 11482	LL
T254	TEST 11498 11507	Potassium
T255	TEST 11509 11514	Serum
T256	TEST 11517 11523	Plasma
T257	TEST 11542 11549	Calcium
T258	TEST 11558 11563	Serum
T259	TEST 11566 11572	Plasma
T260	TEST 11634 11643	Bilirubin
T261	TEST 11645 11650	Total
T262	TEST 11669 11689	Alkaline Phosphatase
T263	TEST 11712 11736	Aspartate 
 transaminase
T264	TEST 11759 11779	Alanine transaminase
T265	TEST 11797 11804	Albumin
T266	TEST 11806 11811	Serum
T267	TEST 11814 11820	Plasma
T268	TEST 11849 11863	Normaliz Ratio
T269	TEST 11921 11927	Cancer
T270	TEST 11928 11935	Antigen
T271	TEST 11965 11979	Cancer Antigen
T272	TEST 12006 12020	Cancer Antigen
T273	TEST 12048 12072	Carcinoembryonic Antigen
T274	TEST 12091 12115	Carcinoembryonic Antigen
T275	TEST 12134 12158	Carcinoembryonic Antigen
T276	TEST 12185 12188	U/S
T277	TREATMENT 12245 12257	paracentesis
T278	PROBLEM 12461 12508	Soft tissue, "superior mesenteric artery margin
T279	PROBLEM 12521 12535	Adenocarcinoma
T280	TEST 12574 12580	biopsy
T281	PROBLEM 12582 12626	Metastatic adenocarcinoma in one lymph  node
T282	TREATMENT 12656 12671	cholecystectomy
T283	PROBLEM 12673 12699	Mild chronic cholecystitis
T284	PROBLEM 12758 12792	significant pathologic abnormality
T285	PROBLEM 12801 12825	tumor in two lymph nodes
T286	TREATMENT 12864 12885	distal pancreatectomy
T287	PROBLEM 12891 12912	Ductal adenocarcinoma
T288	PROBLEM 12932 12952	Chronic pancreatitis
T289	PROBLEM 12973 13004	tumor in twenty-six lymph nodes
T290	TREATMENT 13055 13078	pancreaticoduodenectomy
T291	PROBLEM 13084 13105	Ductal adenocarcinoma
T292	PROBLEM 13107 13132	moderately-differentiated
T293	PROBLEM 13184 13204	Chronic pancreatitis
T294	PROBLEM 13222 13258	Pancreatic intraepithelial neoplasia
T295	PROBLEM 13260 13270	high-grade
T296	PROBLEM 13277 13310	Adenocarcinoma in ten lymph nodes
T297	PROBLEM 13383 13398	Pancreatic head
T298	TREATMENT 13414 13437	Pancreaticoduodenectomy
T299	PROBLEM 13486 13507	Ductal adenocarcinoma
T300	PROBLEM 13565 13583	Invasive Carcinoma
T301	PROBLEM 13585 13610	Moderately-differentiated
T302	TREATMENT 13625 13634	treatment
T303	PROBLEM 13640 13669	Microscopic 
 Tumor Extension
T304	PROBLEM 13671 13693	Tumor invades duodenum
T305	PROBLEM 13734 13757	Lymphovascular Invasion
T306	PROBLEM 13909 13932	invasive adenocarcinoma
T307	PROBLEM 14007 14021	Adenocarcinoma
T308	TEST 14042 14052	the slides
T309	TEST 14067 14091	frozen section diagnosis
T310	PROBLEM 14097 14130	Uncinate (Retroperitoneal) Margin
T311	TREATMENT 14136 14173	the pancreaticoduodenectomy  specimen
T312	PROBLEM 14184 14202	invasive carcinoma
T313	TEST 14262 14278	Bile Duct Margin
T314	PROBLEM 14293 14311	invasive carcinoma
T315	PROBLEM 14316 14337	high-grade  dysplasia
T316	PROBLEM 14339 14357	invasive carcinoma
T317	PROBLEM 14471 14489	invasive carcinoma
T318	PROBLEM 14491 14509	Invasive carcinoma
T319	TEST 14638 14674	the pancreaticoduodenectomy specimen
T320	PROBLEM 14729 14752	invasive adenocarcinoma
T321	TREATMENT 14771 14805	the distal pancreatectomy specimen
T322	PROBLEM 14828 14846	invasive carcinoma
T323	TEST 14911 14929	operative findings
T324	PROBLEM 14989 15011	a true surgical margin
T325	PROBLEM 15056 15074	invasive carcinoma
T326	PROBLEM 15076 15095	invasive  carcinoma
T327	PROBLEM 15191 15209	invasive carcinoma
T328	PROBLEM 15211 15229	invasive carcinoma
T329	TEST 15258 15286	Posterior pancreatic surface
T330	PROBLEM 15298 15316	invasive carcinoma
T331	TEST 15364 15391	Anterior pancreatic surface
T332	PROBLEM 15403 15421	invasive carcinoma
T333	PROBLEM 15484 15498	Residual tumor
T334	TEST 15541 15561	Evans grading system
T335	PROBLEM 15578 15593	Grade I, little
T336	PROBLEM 15608 15630	tumor cell destruction
T337	TEST 15661 15677	tumor regression
T338	PROBLEM 15712 15747	response (extensive residual cancer
T339	PROBLEM 15764 15781	tumor  regression
T340	PROBLEM 15970 15990	Chronic pancreatitis
T341	PROBLEM 16004 16040	pancreatic intraepithelial neoplasia
T342	PROBLEM 16042 16052	high grade
T343	TEST 16102 16122	Immunohistochemistry
T344	TREATMENT 16163 16183	DNA  mismatch repair
T345	TREATMENT 16206 16215	block F11
T346	PROBLEM 16380 16398	Ascites cell block
T347	PROBLEM 16439 16462	KRAS mutations in exons
T348	PROBLEM 16523 16536	resected PDAC
T349	PROBLEM 16595 16621	Resected Pancreatic Cancer
T350	PROBLEM 16624 16640	Positive margins
T351	PROBLEM 16659 16669	recurrence
T352	PROBLEM 16679 16693	rising markers
T353	TEST 16705 16709	Ca19
T354	Radiology 16725 16727	CT
T355	TREATMENT 16794 16799	creon
T356	PROBLEM 16804 16812	LE edema
T357	PROBLEM 16817 16837	abdominal distension
T358	PROBLEM 16857 16865	Diabetes
T359	PROBLEM 16867 16879	poor control
T360	PROBLEM 17054 17077	any concerning symptoms
T361	TREATMENT 17220 17238	the treatment plan
T362	PROBLEM 17243 17251	symptoms
T363	Age 99 101	64
T364	ClinicalCondition 126 143	pancreatic cancer
A2	ContinuityVal T364 stable
A3	ExperiencerVal T364 patient
T365	ProcedureName 117 125	resected
A4	IntentVal T365 treatment-curative
A5	TreatmentContinuityVal T365 finished
A6	TreatmentTypeVal T365 local
A7	TreatmentCategory T365 AntiNeoPlastics
A8	IsTumorRemaining T365 yes
T366	ProcedureName 232 240	resected
A9	IntentVal T366 treatment-curative
A10	TreatmentTypeVal T366 local
A11	IsTumorRemaining T366 yes
T367	ClinicalCondition 241 258	pancreatic cancer
A12	ChronicVal T367 chronic
A13	ContinuityVal T367 stable
A14	ContinuityVal T22 stable
T368	Datetime 405 413	03/19/17
T369	Duration 441 448	3 weeks
A16	IsPresentOnFirstCancerDiagnosis T23 yes
A17	IsCausedByDiagnosedCancer T23 yes
A18	ChronicVal T23 non-chronic
A19	ContinuityVal T23 stopped
R1	Temporal Arg1:T23 Arg2:T369	
A20	IsPresentOnFirstCancerDiagnosis T24 yes
A21	IsCausedByDiagnosedCancer T24 yes
A22	ChronicVal T24 non-chronic
A23	ContinuityVal T24 stopped
A24	ChronicVal T25 non-chronic
A25	ContinuityVal T25 stopped
A26	ExperiencerVal T25 patient
T370	ClinicalCondition 526 544	hyperbilirubinemia
A27	ChronicVal T370 non-chronic
A28	ContinuityVal T370 stopped
A29	ExperiencerVal T370 patient
T371	RadPathResult 552 579	mass at the pancreatic head
A30	RadPathResultVal T371 InitialCancerDiagnosis
R2	HappensBefore Arg1:T368 Arg2:T23	
R3	HappensBefore Arg1:T368 Arg2:T24	
R4	HappensAfter Arg1:T368 Arg2:T371	
R5	HappensBefore Arg1:T368 Arg2:T25	
R6	HappensBefore Arg1:T368 Arg2:T370	
T372	Radiology 612 625	endoscopic US
A31	IntentVal T372 diagnosis
T373	Datetime 583 591	03/26/17
R7	HappensAtOnDuring Arg1:T373 Arg2:T372	
T374	ProcedureName 627 642	stent placement
A32	IntentVal T374 others
A33	TreatmentTypeVal T374 others
A34	TreatmentCategory T374 Supportive
R8	HappensAtOnDuring Arg1:T373 Arg2:T374	
T375	ClinicalCondition 650 670	stricture at the CBD
A35	ChronicVal T375 non-chronic
A36	ContinuityVal T375 stopped
R9	TestOrProcedureConductedForProblem Test:T374 Prob:T375	
T376	ProcedureName 678 694	biopsy/brushings
A37	IntentVal T376 diagnosis
R10	HappensAtOnDuring Arg1:T373 Arg2:T376	
T377	RadPathResult 708 712	mass
A38	RadPathResultVal T377 InitialCancerDiagnosis
R11	HappensAtOnDuring Arg1:T373 Arg2:T377	
T378	Site 735 750	pancreatic head
R12	SiteOf Arg1:T378 Arg2:T377	
T379	ProcedureName 752 774	Fine needle aspiration
A39	IntentVal T379 diagnosis
R13	HappensAtOnDuring Arg1:T373 Arg2:T379	
T380	RadPathResult 790 804	atypical cells
A40	RadPathResultVal T380 NoDisease
R14	ResultOfTest Desc:T380 Test:T379	
T381	RadPathResult 852 872	Hyperechoic material
A41	RadPathResultVal T381 Others
R15	ResultOfTest Desc:T381 Test:T372	
T382	Site 924 936	gallbladder.
R16	SiteOf Arg1:T382 Arg2:T381	
T383	RadPathResult 964 985	significant pathology
A42	NegationModalityVal T383 negated
A43	RadPathResultVal T383 NoDisease
R17	ResultOfTest Desc:T383 Test:T372	
T384	Site 1019 1024	liver
R18	SiteOf Arg1:T384 Arg2:T383	
T385	Datetime 1028 1036	03/30/17
T386	ProcedureName 1042 1060	stent was replaced
A44	IntentVal T386 others
A45	TreatmentTypeVal T386 others
A46	TreatmentCategory T386 Supportive
R19	HappensAtOnDuring Arg1:T385 Arg2:T386	
T387	ClinicalCondition 1079 1110	upward trending total bilirubin
A47	ChronicVal T387 non-chronic
A48	ContinuityVal T387 stopped
A49	ExperiencerVal T387 patient
R20	TestOrProcedureConductedForProblem Test:T386 Prob:T387	
T388	ProcedureName 1112 1118	Biopsy
A50	IntentVal T388 diagnosis
T389	Datetime 1124 1132	03/26/17
R21	HappensAtOnDuring Arg1:T389 Arg2:T388	
A51	RadPathResultVal T41 InitialCancerDiagnosis
R22	ResultOfTest Desc:T41 Test:T388	
A52	IntentVal T42 staging
T390	Stage 1200 1201	3
A53	HistoryVal T390 new
A54	EpisodeDescription T390 FirstOccurrence
T391	Metastasis 1248 1258	metastasis
A55	NegationModalityVal T391 negated
A56	EpisodeDescription T391 FirstOccurrence
A57	IntentVal T45 others
T392	Datetime 1262 1270	04/13/17
R23	HappensAtOnDuring Arg1:T392 Arg2:T45	
T393	ProcedureName 1318 1331	surgical eval
A58	IntentVal T393 others
T394	Datetime 1302 1310	04/20/17
R24	HappensAtOnDuring Arg1:T394 Arg2:T393	
T395	Datetime 1337 1345	06/03/17
T396	Cycles 1347 1351	C1D1
T397	MedicationRegimen 1364 1374	FOLFIRINOX
A59	TreatmentContinuityVal T397 started
A60	TreatmentTypeVal T397 neoadjuvant
A61	TreatmentIntentVal T397 curative
R25	TreatmentDesc Therapy:T396 Desc:T397	
T398	Datetime 1377 1385	10/20/17
T399	Radiology 1387 1394	CT scan
A62	IntentVal T399 TreatmentAssessment
R27	HappensAtOnDuring Arg1:T398 Arg2:T399	
T400	RadPathResult 1396 1402	Stable
A63	RadPathResultVal T400 DiseaseStability
R28	ResultOfTest Desc:T400 Test:T399	
T401	RadPathResult 1404 1422	no e/o progression
A64	RadPathResultVal T401 DiseaseStability
R29	ResultOfTest Desc:T401 Test:T399	
T402	Datetime 1425 1433	11/05/17
R26	BeginsOnOrAt Arg1:T395 Arg2:T397	
T403	Cycles 1441 1443	12
T404	MedicationRegimen 1444 1454	FOLFIRINOX
A65	TreatmentContinuityVal T404 finished
A66	TreatmentTypeVal T404 neoadjuvant
A67	TreatmentIntentVal T404 curative
R30	TreatmentDesc Therapy:T403 Desc:T404	
R31	EndsOnOrAt Arg1:T402 Arg2:T404	
T405	Datetime 1470 1478	01/25/18
T406	ProcedureName 1480 1487	Whipple
A68	IntentVal T406 treatment-curative
A69	TreatmentTypeVal T406 local
A70	TreatmentCategory T406 Others
A71	IsTumorRemaining T406 yes
T407	ProcedureName 1514 1538	pancreatico-duodenectomy
A72	IntentVal T407 treatment-curative
A73	TreatmentTypeVal T407 local
A74	TreatmentCategory T407 Others
A75	IsTumorRemaining T407 yes
T408	ProcedureName 1544 1567	pancreatico-jejunostomy
A76	IntentVal T408 treatment-curative
A77	TreatmentTypeVal T408 local
A78	TreatmentCategory T408 Others
A79	IsTumorRemaining T408 yes
R32	HappensAtOnDuring Arg1:T405 Arg2:T406	
R33	HappensAtOnDuring Arg1:T405 Arg2:T407	
R34	HappensAtOnDuring Arg1:T405 Arg2:T408	
T409	Pathology 1577 1586	op report
A80	IntentVal T409 TreatmentAssessment
T410	RadPathResult 1588 1624	mass was adherent to the portal vein
A81	RadPathResultVal T410 Others
R35	ResultOfTest Desc:T410 Test:T409	
T411	Pathology 1626 1635	Pathology
A82	IntentVal T411 TreatmentAssessment
R36	HappensAtOnDuring Arg1:T405 Arg2:T409	
R37	HappensAtOnDuring Arg1:T405 Arg2:T411	
T412	LocalInvasion 1687 1691	+PNI
A83	EpisodeDescription T412 FirstOccurrence
T413	Size 1645 1650	4.6cm
A84	EpisodeDescription T413 FirstOccurrence
T414	MarginStatus 1693 1714	+SM at the SMA margin
A85	MarginVal T414 positive
R38	TestOrProcedureReveals Test:T411 Desc:T413	
R39	TestOrProcedureReveals Test:T411 Desc:T412	
T415	LymphNodeInvolvement 1720 1725	11/46
A86	EpisodeDescription T415 FirstOccurrence
R40	TestOrProcedureReveals Test:T411 Desc:T415	
R41	ProcedureDesc Procedure:T406 Desc:T414	
T416	ClinicalCondition 1794 1809	wound infection
A87	ChronicVal T416 non-chronic
A88	ContinuityVal T416 stopped
A89	ExperiencerVal T416 patient
R42	HappensAfter Arg1:T405 Arg2:T416	
T417	Site 1822 1835	neck incision
T418	Laterality 1817 1821	left
R43	LateralityOfSite Arg1:T418 Arg2:T417	
R44	SiteOf Arg1:T417 Arg2:T416	
T419	Duration 1885 1892	1 month
T420	TreatmentType 1896 1901	rehab
A90	TreatmentContinuityVal T420 finished
A91	TreatmentTypeVal T420 others
R45	Temporal Arg1:T419 Arg2:T420	
T421	Datetime 1929 1937	03/24/18
R46	EndsOnOrAt Arg1:T421 Arg2:T420	
T422	Datetime 1940 1948	04/15/18
T423	Radiology 1952 1958	CT CAP
A92	IntentVal T423 TreatmentAssessment
R47	HappensAtOnDuring Arg1:T422 Arg2:T423	
T424	RadPathResult 1967 1988	ill defined stranding
A93	RadPathResultVal T424 Progression
T425	Site 1992 2014	surgical resection bed
R48	SiteOf Arg1:T425 Arg2:T424	
R49	ResultOfTest Desc:T424 Test:T423	
T426	RadPathResult 2031 2041	recurrence
A94	RadPathResultVal T426 Progression
R50	ResultOfTest Desc:T426 Test:T423	
T427	RadPathResult 2045 2066	post-surgical changes
A95	RadPathResultVal T427 NoDisease
R51	ResultOfTest Desc:T427 Test:T423	
T428	Metastasis 2134 2144	metastatic
A96	NegationModalityVal T428 negated
R52	TestOrProcedureReveals Test:T423 Desc:T428	
T429	Datetime 2155 2163	04/21/18
T430	ProcedureName 2165 2177	Consultation
A97	IntentVal T430 others
R53	HappensAtOnDuring Arg1:T429 Arg2:T430	
T431	DiseaseState 2258 2268	recurrence
A98	NegationModalityVal T431 uncertain_in_present
T432	MarginStatus 2274 2283	+ margins
A99	MarginVal T432 positive
R54	ProcedureDesc Procedure:T406 Desc:T432	
T433	Site 2291 2294	SMA
T434	LymphNodeInvolvement 2299 2316	many LNs involved
A100	EpisodeDescription T434 FirstOccurrence
T435	RadiationTherapyName 2358 2361	XRT
A101	TreatmentContinuityVal T435 unclear
A102	TreatmentTypeVal T435 local
A103	TreatmentIntentVal T435 curative
T436	TreatmentType 2371 2387	systemic therapy
A104	TreatmentContinuityVal T436 unclear
A105	TreatmentTypeVal T436 adjuvant
A106	TreatmentIntentVal T436 curative
T437	Radiology 2453 2459	PET/CT
A107	IntentVal T437 staging
T438	TreatmentType 2478 2490	radiotherapy
A108	NegationModalityVal T438 planned_in_future
A109	NegationModalityVal T436 hypothetical_in_future
A110	NegationModalityVal T435 hypothetical_in_future
A111	NegationModalityVal T437 planned_in_future
T439	RadiationTherapyName 2492 2496	IMRT
A112	TreatmentContinuityVal T439 planned
A113	TreatmentTypeVal T439 local
A114	TreatmentIntentVal T439 curative
T440	Cycles 2524 2526	28
R55	TreatmentDesc Therapy:T439 Desc:T440	
T441	ProcedureName 2548 2554	CT sim
A115	IntentVal T441 others
T442	Duration 2558 2566	~2 weeks
R56	BeginsOnOrAt Arg1:T442 Arg2:T441	
A116	NegationModalityVal T441 planned_in_future
T443	ClinicalCondition 2587 2607	C dificile infection
A117	ChronicVal T443 non-chronic
A118	ContinuityVal T443 improving
T444	Duration 2629 2636	2 weeks
T445	ProcedureName 2674 2677	sim
A119	IntentVal T445 others
A120	TreatmentTypeVal T445 others
R57	HappensAfter Arg1:T445 Arg2:T444	
T446	Datetime 2682 2690	May 2018
A121	ChronicVal T73 non-chronic
A122	ContinuityVal T73 new
R58	HappensAtOnDuring Arg1:T446 Arg2:T73	
T447	ProcedureName 2742 2754	paracentesis
A123	IntentVal T447 others
A124	TreatmentTypeVal T447 others
A125	TreatmentCategory T447 Supportive
T448	Frequency 2735 2741	weekly
R59	Temporal Arg1:T447 Arg2:T448	
T449	Site 2756 2769	Ascites fluid
T450	RadPathResult 2773 2796	negative for malignancy
A126	RadPathResultVal T450 NoDisease
R60	SiteOf Arg1:T449 Arg2:T450	
T451	GenomicTest 2805 2809	KRAS
A127	NegationModalityVal T451 negated
A128	IntentVal T451 diagnosis
A129	GenomicTestType T451 Somatic
R61	SiteOf Arg1:T449 Arg2:T451	
T452	ClinicalCondition 2819 2826	Ascites
A130	ChronicVal T452 non-chronic
T453	RadPathResult 2859 2879	portal vein stenosis
A131	RadPathResultVal T453 Others
T454	RadPathResult 2926 2934	thrombus
A132	NegationModalityVal T454 negated
A133	RadPathResultVal T454 Others
T455	Datetime 2938 2947	June 2018
T456	ProcedureName 2961 2968	stented
A134	IntentVal T456 others
A135	TreatmentTypeVal T456 others
A136	TreatmentCategory T456 Supportive
T457	Site 2949 2960	Portal vein
R62	SiteOf Arg1:T457 Arg2:T456	
T458	ClinicalCondition 2985 2992	Ascites
A137	ChronicVal T458 non-chronic
A138	ContinuityVal T458 stopped
T459	Datetime 2996 3008	September 08
T460	Radiology 3014 3020	PET CT
A139	IntentVal T460 TreatmentAssessment
R63	HappensAtOnDuring Arg1:T459 Arg2:T460	
T461	Datetime 3022 3032	October 08
T462	Radiology 3038 3045	abd U/s
A140	IntentVal T462 TreatmentAssessment
R64	HappensAtOnDuring Arg1:T461 Arg2:T462	
T463	RadPathResult 3050 3057	ascites
A141	NegationModalityVal T463 negated
A142	RadPathResultVal T463 Others
R65	ResultOfTest Desc:T463 Test:T462	
T464	RadPathResult 3010 3013	Neg
A143	RadPathResultVal T464 NoDisease
R66	ResultOfTest Desc:T464 Test:T460	
T465	DiagnosticLabTest 3134 3140	HgBA1C
A144	ChronicVal T465 chronic
A145	ContinuityVal T465 stable
T466	Symptom 3157 3161	pain
A146	NegationModalityVal T466 negated
T467	ClinicalCondition 3163 3169	Wounds
A147	ChronicVal T467 non-chronic
A148	ContinuityVal T467 stopped
T468	Symptom 3236 3242	chills
A149	NegationModalityVal T468 negated
T469	Symptom 3244 3249	fever
A150	NegationModalityVal T469 negated
T470	Symptom 3254 3261	malaise
A151	NegationModalityVal T470 negated
T471	Symptom 3262 3269	fatigue
A152	NegationModalityVal T471 negated
T472	Symptom 3322 3335	double vision
A153	NegationModalityVal T472 negated
T473	Symptom 3340 3344	pain
A154	NegationModalityVal T473 negated
T474	Symptom 3374 3379	cough
A155	NegationModalityVal T474 negated
A156	NegationModalityVal T98 negated
A157	NegationModalityVal T99 negated
A158	NegationModalityVal T100 negated
A159	NegationModalityVal T101 negated
A160	NegationModalityVal T102 negated
A161	NegationModalityVal T103 negated
A162	NegationModalityVal T104 negated
A163	NegationModalityVal T105 negated
A164	NegationModalityVal T106 negated
A165	NegationModalityVal T107 negated
A166	NegationModalityVal T108 negated
A167	NegationModalityVal T109 negated
A168	NegationModalityVal T110 negated
A169	NegationModalityVal T111 negated
A170	NegationModalityVal T112 negated
A171	NegationModalityVal T113 negated
A172	NegationModalityVal T114 negated
A173	NegationModalityVal T115 negated
A174	NegationModalityVal T116 negated
A175	NegationModalityVal T117 negated
A176	NegationModalityVal T118 negated
T475	Drugs 3933 3948	substance abuse
A177	NegationModalityVal T475 negated
T476	Symptom 3969 3976	nervous
A178	NegationModalityVal T476 negated
T477	Symptom 3977 3984	anxious
A179	NegationModalityVal T477 negated
T478	Symptom 4003 4011	insomnia
A180	NegationModalityVal T478 negated
T479	Allergy 7549 7560	Ondansetron
A181	NegationModalityVal T479 affirmed
T480	Allergy 7681 7692	Oxaliplatin
A182	NegationModalityVal T480 affirmed
T481	Allergy 7995 8012	Sodium Phosphates
A183	NegationModalityVal T481 affirmed
T482	Allergy 8148 8158	Acesulfame
A184	NegationModalityVal T482 affirmed
T483	Allergy 8221 8241	Monosodium Glutamate
A185	NegationModalityVal T483 affirmed
T484	Allergy 8326 8337	Penicillins
A186	NegationModalityVal T484 affirmed
T485	Symptom 7746 7754	numbness
A187	ContinuityVal T485 stopped
A189	ContinuityVal T196 stopped
A190	ContinuityVal T197 stopped
A191	ContinuityVal T199 stopped
A192	ContinuityVal T201 stopped
A193	ContinuityVal T202 stopped
T486	Symptom 8184 8194	Exhaustion
A194	ContinuityVal T486 stopped
T487	Symptom 8302 8321	redness on his lips
A195	ContinuityVal T487 stopped
T488	Symptom 8363 8371	Numbness
A196	ContinuityVal T488 stopped
T489	Symptom 8431 8450	heaviness of tongue
A197	ContinuityVal T489 stopped
T490	Symptom 8452 8460	numbness
A198	ContinuityVal T490 stopped
T491	Age 16505 16507	64
T492	ClinicalCondition 16532 16536	PDAC
A199	ContinuityVal T492 stable
T493	ProcedureName 16523 16531	resected
A200	IntentVal T493 treatment-curative
A201	TreatmentTypeVal T493 local
A202	TreatmentCategory T493 AntiNeoPlastics
T494	TNM 16538 16543	pT2N3
A203	EpisodeDescription T494 FirstOccurrence
T495	MarginStatus 16545 16546	+
A204	MarginVal T495 positive
T496	Site 16547 16573	superior mesenteric artery
T497	ProcedureName 16595 16603	Resected
A205	IntentVal T497 treatment-curative
A206	TreatmentTypeVal T497 local
A207	TreatmentCategory T497 AntiNeoPlastics
A208	IsTumorRemaining T497 yes
A209	IsTumorRemaining T493 yes
T498	ClinicalCondition 16604 16621	Pancreatic Cancer
A210	ChronicVal T498 chronic
A211	ContinuityVal T498 stable
T499	MarginStatus 16624 16632	Positive
A212	MarginVal T499 positive
T500	DiseaseState 16659 16669	recurrence
A213	NegationModalityVal T500 hypothetical_in_future
T501	LabTestResult 16686 16693	markers
A214	LabTestResultVal T501 abnormal
T502	DiagnosticLabTest 16705 16711	Ca19-9
A215	IntentVal T502 TreatmentAssessment
R67	ResultOfTest Desc:T501 Test:T502	
A216	IntentVal T354 TreatmentAssessment
T503	Duration 16731 16738	2 weeks
R68	HappensAfter Arg1:T503 Arg2:T354	
A217	NegationModalityVal T354 planned_in_future
A218	NegationModalityVal T502 planned_in_future
T504	MedicationName 16794 16799	creon
A219	TreatmentContinuityVal T504 continuing
A220	TreatmentTypeVal T504 others
A221	TreatmentIntentVal T504 others
A222	TreatmentCategory T504 Supportive
T505	TreatmentDosage 16801 16802	3
R69	TreatmentDesc Therapy:T504 Desc:T505	
T506	Symptom 16807 16812	edema
A223	IsPresentOnFirstCancerDiagnosis T506 no
A224	IsCausedByDiagnosedCancer T506 unclear
A225	ChronicVal T506 chronic
A226	ContinuityVal T506 improving
T507	Symptom 16827 16837	distension
A227	IsPresentOnFirstCancerDiagnosis T507 no
A228	IsCausedByDiagnosedCancer T507 unclear
A229	ChronicVal T507 chronic
A230	ContinuityVal T507 improving
T508	Site 16817 16826	abdominal
T509	Site 16804 16806	LE
R70	SiteOf Arg1:T509 Arg2:T506	
R71	SiteOf Arg1:T508 Arg2:T507	
T510	ClinicalCondition 16857 16865	Diabetes
A231	ChronicVal T510 chronic
A232	ContinuityVal T510 stable
T511	MaritalStatus 8640 8647	Married
A233	IsStoppedOrContinuing T511 continuing
T512	Tobacco 9003 9015	Never Smoker
A234	NegationModalityVal T512 negated
T513	Tobacco 9039 9049	Never Used
A235	NegationModalityVal T513 negated
T514	Tobacco 9099 9101	No
A236	NegationModalityVal T514 negated
T515	Datetime 9151 9159	04/19/17
T516	Alcohol 9146 9150	ETOH
A237	IsStoppedOrContinuing T516 stopped
R72	HappensAtOnDuring Arg1:T515 Arg2:T516	
T517	Tobacco 9174 9176	No
A238	NegationModalityVal T517 negated
T518	Symptom 7561 7569	Wheezing
A239	IsCausedByDiagnosedCancer T518 no
A240	ChronicVal T518 non-chronic
A241	ContinuityVal T518 stopped
T519	Symptom 7579 7587	wheezing
A242	IsCausedByDiagnosedCancer T519 no
A243	ChronicVal T519 non-chronic
A244	ContinuityVal T519 stopped
T520	Symptom 7613 7623	closing up
A245	IsCausedByDiagnosedCancer T520 no
A246	ChronicVal T520 non-chronic
A247	ContinuityVal T520 stopped
T521	Symptom 7630 7640	coarseness
A248	IsCausedByDiagnosedCancer T521 no
A249	ChronicVal T521 non-chronic
A250	ContinuityVal T521 stopped
T190	Symptom 7781 7788	Redness
A188	IsCausedByDiagnosedCancer T190 no
A251	ChronicVal T190 non-chronic
A252	ContinuityVal T190 stopped
T522	Site 7644 7650	throat
T523	Site 7773 7779	tongue
T524	Site 7792 7800	forehead
R73	SiteOf Arg1:T523 Arg2:T485	
A253	TreatmentContinuityVal T191 finished
A254	TreatmentTypeVal T191 others
A255	TreatmentIntentVal T191 others
A256	TreatmentCategory T191 Supportive
R74	TreatmentAdministeredForProblem Treatment:T191 Prob:T485	
A257	TreatmentContinuityVal T192 finished
A258	TreatmentTypeVal T192 others
A259	TreatmentIntentVal T192 others
A260	TreatmentCategory T192 Supportive
R75	TreatmentAdministeredForProblem Treatment:T192 Prob:T485	
T525	MedicationName 7865 7875	irinotecan
A261	TreatmentContinuityVal T525 finished
A262	TreatmentTypeVal T525 neoadjuvant
A263	TreatmentIntentVal T525 curative
A264	TreatmentCategory T525 AntiNeoPlastics
T526	MedicationName 7880 7890	leucovorin
A265	TreatmentContinuityVal T526 finished
A266	TreatmentTypeVal T526 neoadjuvant
A267	TreatmentIntentVal T526 curative
A268	TreatmentCategory T526 AntiNeoPlastics
T527	Site 8381 8386	thigh
R76	SiteOf Arg1:T527 Arg2:T488	
T528	Site 8472 8478	throat
R77	SiteOf Arg1:T528 Arg2:T490	
A269	TreatmentContinuityVal T209 finished
A270	TreatmentTypeVal T209 others
A271	TreatmentIntentVal T209 others
A272	TreatmentCategory T209 Others
A273	TreatmentContinuityVal T210 finished
A274	TreatmentTypeVal T210 others
A275	TreatmentIntentVal T210 others
A276	TreatmentCategory T210 Supportive
A277	ChronicVal T122 chronic
A278	ContinuityVal T122 stable
A279	ChronicVal T126 chronic
A280	ContinuityVal T126 stable
A281	ChronicVal T127 chronic
A282	ContinuityVal T127 stable
A283	ChronicVal T130 chronic
A284	ContinuityVal T130 stable
T529	TreatmentType 4133 4168	continuous positive airway pressure
A285	TreatmentContinuityVal T529 continuing
A286	TreatmentTypeVal T529 others
A287	TreatmentIntentVal T529 others
T530	TreatmentType 4169 4183	(CPAP) therapy
A288	TreatmentContinuityVal T530 continuing
A289	TreatmentTypeVal T530 others
A290	TreatmentIntentVal T530 others
A291	TreatmentContinuityVal T125 continuing
A292	TreatmentTypeVal T125 others
A293	TreatmentIntentVal T125 others
T531	ProcedureName 4884 4897	TONSILLECTOMY
A294	IntentVal T531 others
A295	TreatmentTypeVal T531 others
A296	TreatmentCategory T531 Others
T532	ProcedureName 4825 4840	STENT PLACEMENT
A297	IntentVal T532 others
A298	TreatmentTypeVal T532 others
A299	TreatmentCategory T532 Others
T533	ProcedureName 4775 4800	LAPAROSCOPIC APPENDECTOMY
A300	IntentVal T533 others
A301	TreatmentTypeVal T533 others
A302	TreatmentCategory T533 Others
T534	ProcedureName 4592 4609	IR PORT PLACEMENT
A303	IntentVal T534 others
A304	TreatmentTypeVal T534 others
A305	TreatmentCategory T534 Others
T535	ProcedureName 4667 4684	IR PORT PLACEMENT
A306	IntentVal T535 others
A307	TreatmentTypeVal T535 others
A308	TreatmentCategory T535 Others
T536	ProcedureName 4470 4482	APPENDECTOMY
A309	IntentVal T536 others
A310	TreatmentTypeVal T536 others
A311	TreatmentCategory T536 Others
T537	ProcedureName 4501 4505	ERCP
A312	IntentVal T537 others
A313	TreatmentTypeVal T537 others
A314	TreatmentCategory T537 Others
T538	Datetime 4802 4812	06/08/2010
T539	Datetime 4184 4188	2011
T540	Datetime 4327 4331	2015
T541	Datetime 4488 4496	May 2010
T542	Datetime 4507 4511	2018
T543	Datetime 4554 4562	03/26/17
T544	Datetime 4579 4587	03/30/17
T545	Datetime 4653 4663	04/28/2017
T546	Datetime 4727 4737	04/28/2017
T547	Datetime 4869 4879	March 2017
T548	Datetime 4907 4914	1960-62
R78	HappensAtOnDuring Arg1:T538 Arg2:T533	
R79	HappensAtOnDuring Arg1:T547 Arg2:T532	
R80	HappensAtOnDuring Arg1:T548 Arg2:T531	
R81	HappensAtOnDuring Arg1:T545 Arg2:T535	
R82	HappensAtOnDuring Arg1:T544 Arg2:T534	
T549	ProcedureName 4564 4578	replaced stent
A348	IntentVal T549 others
A349	TreatmentTypeVal T549 others
A350	TreatmentCategory T549 Others
R83	HappensAtOnDuring Arg1:T543 Arg2:T549	
R84	HappensAtOnDuring Arg1:T537 Arg2:T542	
R85	HappensAtOnDuring Arg1:T536 Arg2:T541	
A351	IntentVal T129 others
T550	SectionSkip 4920 5872;5875 7486	Current Medications       Dosage    acetaminophen (TYLENOL) 500 mg tablet Take 1,000 mg by mouth 2 (two) times daily as needed for Pain.     alpha-D-galactosidase (BEANO ORAL) Take by mouth. not taking, patient do not have supplies    blood glucose (BLOOD GLUCOSE) test strip Check blood sugar 4x daily, as directed    blood-glucose monitoring kit Check glucose daily as directed by provider    calcium carbonate (TUMS ORAL) Take 1,000 mg by mouth once as needed.    calcium citrate/vitamin D3 (CALCIUM CITRATE + D ORAL) Take by mouth Daily.    cholecalciferol, vitamin D3, 1000 UNITS TAB tablet Take 1,000 Units by mouth Daily.    clotrimazole 1 mg/mL SUSP suspension Take by mouth daily as needed. buccal    empty container (SHARPS CONTAINER) MISC Sharps Container: Use as directed to discard insulin needles and lancets with each use.    enoxaparin (LOVENOX) 80 mg/0.8 mL injection Inject 60 mg under the skin every 12 (twelve) hours.     famotidine (PEPCID) 10 mg tablet Take 10 mg by mouth 2 (two) times daily as needed (indigestion).    folic acid/multivit-min/lutein (CENTRUM SILVER ORAL) Take by mouth Daily.    furosemide (LASIX) 20 mg tablet Take 20 mg by mouth Daily.     glucose 4 gram chewable tablet When Blood sugar <70mg/dL, chew and swallow 20grams (5 tablets) and restest blood sugar in 15 minutes to goal blood sugar >100mg/dL    insulin aspart U-100 (NOVOLOG) 100 unit/mL injection Inject under the skin three times daily with meals and at bedtime according to your insulin sliding scale    insulin glargine (LANTUS) 100 unit/mL injection Inject 14 Units under the skin Daily. Or as directed. Note that your dose may change.    insulin syringe-needle U-100 (BD INSULIN SYRINGE ULTRA-FINE) 0.3 mL 31 gauge x August 05" SYRINGE syringe Use four times daily as directed.    lancets lancets Check blood sugar 4x per day as directed.    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit CAPDREC capsule Take 6 capsules by mouth 3 (three) times daily. 3 capsules with snacks    multivitamin complete chewable (FLINTSTONES COMPLETE) chewable tablet Take 1 tablet by mouth Daily.    pantoprazole (PROTONIX) 40 mg EC tablet Take 40 mg by mouth 2 (two) times daily.    rifAXIMin (XIFAXAN) 550 mg tablet Take 550 mg by mouth 2 (two) times daily.    rivaroxaban (XARELTO) 20 mg tablet Take 20 mg by mouth Daily. On hold by *****. ***** ***** / pt is on Lovenox - SFGH    Saccharomyces boulardii (FLORASTOR) 250 mg capsule Take 250 mg by mouth 2 (two) times daily.    vancomycin (VANCOCIN) 125 mg capsule Take 125 mg by mouth 4 (four) times daily.
A352	SectionSkipType T550 medications
T551	SectionSkip 7496 7824;7827 8570	Allergies/Contraindications   Allergen Reactions    Ondansetron Wheezing     Felt wheezing, throat felt like it was closing up. Some coarseness in throat. Occurred in the hospital    Oxaliplatin Other (See Comments)     40min into infusion, pt c/o numbness on the tip of his tongue. Redness on forehead noted.  Benadryl IV and hydrocortisone given, remaining chemo irinotecan and leucovorin completed without complication. Patient reports heaviness of tongue and numbness at back of throat.    Sodium Phosphates Other (See Comments) and Wheezing     Patient states that 3rd dosage of saline fleet enema results in wheezing and chest tightness    Acesulfame Other (See Comments)     Exhaustion, slept for over a day    Monosodium Glutamate Other (See Comments)     Patient states that MSG results in redness on his lips    Penicillins Other (See Comments)     Numbness on right thigh,minor reaction per patient. Patient reports heaviness of tongue, numbness at back of throat.  Was given ertapenem and fleet enema around this time and thinks it may be caused by this.
A353	SectionSkipType T551 allergies
T15	SectionSkip 12178 12400	Rads:  U/S Abd: 10/07/18    IMPRESSION:     Insufficient fluid for paracentesis.    Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD  Department of Radiology and Biomedical Imaging    Path from surgery
A356	SectionSkipType T15 radiology_report
A354	SectionSkipType T8 physical_exam
T10	SectionSkip 11063 11721;11724 12173	LABORATORY RESULTS  I have reviewed the following labs in clinic today and discussed them with the patient.  Lab Results   Component Value Date    WBC Count 6.4 09/05/2018    Neutrophil Absolute Count 4.43 09/05/2018    Hemoglobin 9.5 (L) 09/05/2018    Hematocrit 29.0 (L) 09/05/2018    Platelet Count 412 09/05/2018     Lab Results   Component Value Date    Creatinine 0.67 09/05/2018    Sodium, Serum / Plasma 123 (LL) 09/05/2018    Potassium, Serum / Plasma 4.7 09/05/2018    Calcium, total, Serum / Plasma 8.7 (L) 09/05/2018     Lab Results   Component Value Date    Bilirubin, Total 0.5 09/05/2018    Alkaline Phosphatase 665 (H) 09/05/2018    Aspartate transaminase 101 (H) 09/05/2018    Alanine transaminase 58 09/05/2018    Albumin, Serum / Plasma 3.3 (L) 09/05/2018    Int'l Normaliz Ratio 1.0 05/24/2018     Lab Results   Component Value Date    Cancer Antigen 19-9 4,375 (H) 08/30/2018    Cancer Antigen 19-9 48 (H) 04/14/2018    Cancer Antigen 19-9 182 (H) 10/21/2017    Carcinoembryonic Antigen 1.0 10/21/2017    Carcinoembryonic Antigen 1.2 09/23/2017    Carcinoembryonic Antigen 1.9 08/26/2017
A357	SectionSkipType T10 laboratory
T11	SectionSkip 12401 13651;13654 15575;15578 16474	:  Service Date: 01/25/2018  FINAL PATHOLOGIC DIAGNOSIS  A. Soft tissue, "superior mesenteric artery margin," biopsy:   Adenocarcinoma; see comment.   B. Celiac lymph node, biopsy: Metastatic adenocarcinoma in one lymph  node (March 22).  C. Gallbladder, cholecystectomy: Mild chronic cholecystitis.  D. Spleen, splenectomy:   1. Spleen (564 grams) with no significant pathologic abnormality.  2. No tumor in two lymph nodes (0/2).    E. Pancreas, tail and body, distal pancreatectomy:  1. Ductal adenocarcinoma; see comment.   2. Chronic pancreatitis, extensive.   3. No tumor in twenty-six lymph nodes (0/26).       F. Pancreas, duodenum, portal vein, pancreaticoduodenectomy:  1. Ductal adenocarcinoma, moderately-differentiated, 4.6 cm, involving  duodenal wall; see comment  2. Chronic pancreatitis, extensive.   3. Pancreatic intraepithelial neoplasia, high-grade.   4. Adenocarcinoma in ten lymph nodes (January 06).    COMMENT:  PANCREAS SYNOPTIC COMMENT  - Tumor Location: Pancreatic head.  - Procedure: Pancreaticoduodenectomy.  - Size: Unifocal, 4.6 cm.  - Histologic Type: Ductal adenocarcinoma (slides F1, F4, F5, and  F8-F15).  - Histologic Grade of Invasive Carcinoma: Moderately-differentiated  (status post treatment).  - Microscopic Tumor Extension: Tumor invades duodenum and tunica media  of portal vein.     - Lymphovascular Invasion: Not identified.  - Perineural Invasion: Present.  - Margins:    Superior mesenteric artery margin: In the separately submitted "SMA  margin" (part A) invasive adenocarcinoma is present on permanent and  deeper level sections performed on block A1. Adenocarcinoma was not  present on the slides evaluated for frozen section diagnosis.     Uncinate (Retroperitoneal) Margin: For the pancreaticoduodenectomy  specimen (part F), invasive carcinoma is less than 0.1 cm from  cauterized margin on slide F5.   Bile Duct Margin: Negative for invasive carcinoma and high-grade  dysplasia, invasive carcinoma is 0.5 cm from margin.  Portal Vein Margin: Both the superior and inferior portal vein margins  are negative for invasive carcinoma. Invasive carcinoma is 0.8 cm from  the superior portal vein margin and 2.3 cm from the inferior portal vein  margin.   Pancreatic Neck Margin: For the pancreaticoduodenectomy specimen (part  F), the pancreatic neck margin is positive for invasive adenocarcinoma  on slide F1. For the distal pancreatectomy specimen (part E), a focus of  invasive carcinoma is present at the proximal pancreatic margin.  Correlation with operative findings is recommended to determine if  either of these represents a true surgical margin.   Proximal Intestinal Margin: Negative for invasive carcinoma, invasive  carcinoma is 6 cm from the margin.  Distal Intestinal Margin (Distal Duodenal or Jejunal): Negative for  invasive carcinoma, invasive carcinoma is 9 cm from the margin.  - Posterior pancreatic surface: Negative, invasive carcinoma is 0.1 cm  from this surface on slide F13.   - Anterior pancreatic surface: Negative, invasive carcinoma is 1 cm  from this surface on slide F12.  - Treatment Effect: Residual tumor on slides E1, F1, F4, F5, and  F8-F16.    Evans grading system (grade I-IV): Grade I, little (<10%) or no  tumor cell destruction.     Modified Ryan scheme for tumor regression (score 0-3): Score 3,  poor or no response (extensive residual cancer with no evident tumor  regression).  - Regional Lymph Nodes: Positive.    Total number of positive nodes: 11.    Nodes involved by direct extension: 4.     Total number of nodes examined: 46.  - Other Pathologic Findings: Chronic pancreatitis, extensive;  pancreatic intraepithelial neoplasia, high grade.   AJCC 8th Edition Pathologic Stage: ypT3N2.    Immunohistochemistry was performed to evaluate the status of DNA  mismatch repair protein expression on block F11. The results in the  tumor cell nuclei are:  MLH1 expression: Present.   PMS2 expression: Present.  MSH2 expression: Present.  MSH6 expression: Present.  05/20/18: Ascites cell block interpreted as benign, and negative for KRAS mutations in exons 2, 3 and 4.
A358	SectionSkipType T11 pathology_report
T12	Histology 1667 1680	adenocarcinom
A359	EpisodeDescription T12 FirstOccurrence
T17	Site 1651 1666	pancreatic head
R86	SiteOf Arg1:T17 Arg2:T12	
R87	TestOrProcedureReveals Test:T411 Desc:T12	
T552	Datetime 2390 2398	05/04/18
R88	TestOrProcedureConductedForProblem Test:T447 Prob:T73	
T553	ProcedureName 2902 2909	surgery
A360	TreatmentContinuityVal T553 finished
A361	TreatmentTypeVal T553 local
A362	TreatmentIntentVal T553 curative
R89	HappensAtOnDuring Arg1:T455 Arg2:T456	
T554	Radiology 2845 2847	CT
A363	IntentVal T554 unclear
R90	ResultOfTest Desc:T453 Test:T554	
R91	ResultOfTest Desc:T454 Test:T554	
A364	TreatmentCategory T553 AntiNeoPlastics
A365	IsTumorRemaining T553 no
T555	LabTestResult 3149 3152	>12
A366	LabTestResultVal T555 abnormal
R92	ResultOfTest Desc:T555 Test:T465	
R93	BeginsOnOrAt Arg1:T539 Arg2:T530	
T556	DiagnosticLabTest 4323 4326	PPD
A367	IntentVal T556 others
T557	LabTestResult 4314 4322	Positive
A368	LabTestResultVal T557 abnormal
R94	ResultOfTest Desc:T557 Test:T556	
R95	HappensAtOnDuring Arg1:T540 Arg2:T556	
R96	HappensAtOnDuring Arg1:T540 Arg2:T129	
A355	DiseaseStateVal T500 progression-recurrence
A369	DiseaseStateVal T431 progression-recurrence
R98	ProcedureDesc Procedure:T497 Desc:T499	
R99	SizeOf Arg1:T413 Arg2:T12	
T14	hpi_start 0 6	REASON
T558	ap_start 16479 16489	Assessment
T559	ap_end 17091 17099	interim.
T560	hpi_end 3170 3179	improved.
R100	HappensAtOnDuring Arg1:T396 Arg2:T395	
R101	HappensAtOnDuring Arg1:T402 Arg2:T403	
